Oncoinvent ASA – Mandatory notification of trade
Reference is made to the retail offering (the “Retail O … Read more
Oncoinvent ASA – Disclosure of large shareholding
Reference is made to the stock exchange announcement by … Read more
Oncoinvent ASA – Ex. date
The shares in Oncoinvent ASA will from today, 23 Septem … Read more
Oncoinvent ASA – Mandatory notification of trade – Allocation and share lending in Private Placement
Oslo, 23 September 2026: Reference is made to the stock … Read more
Oncoinvent ASA – Mandatory notification of trade
Reference is made to the private placement (the “Privat … Read more
Oncoinvent ASA – Key information relating to subsequent offering
Reference is made to the stock exchange announcement ma … Read more
Oncoinvent ASA – Successful Private Placement and Retail Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY … Read more
Oncoinvent ASA – Contemplated private placement and retail offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY … Read more
Oncoinvent presents first half 2026 results
Oslo, Norway, 27 August 2026 – Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its first half 2026 results.
Oslo, Norway, 17 August 2026 – Oncoinvent ASA (ONCIN), … Read more